PTAB prevails against ‘Big Tech’ bias complaint
21-09-2022
Fintiv-based PTAB decision faces scrutiny from Vidal
05-09-2022
Michael Vi / Shutterstock.com
With the addition of USPTO director reviews and some key cases, the Patent Trial and Appeal Board has once again had a remarkable year, finds Muireann Bolger.
This year marked an upturn in fortunes for the Patent Trial and Appeal Board (PTAB).
After securing some key wins at the behest of both the US Patent and Trademark Office (USPTO) and the US Court of Appeals for the Federal Circuit—it has cemented its position as a dominant force in patent litigation.
A tumultuous history
The rest of this article is locked for subscribers only. Please login to continue reading.
If you don't have a login, you will need to purchase a subscription to gain access to this article, including all our online content. Please use this link and follow the steps.
For multi-user price options, or to check if your company has an existing subscription to us that we can add you to for FREE, please email Atif Choudhury at achoudhury@worldipreview.com
PTAB, USPTO, Federal Circuit, patent invalidation, Arthrex, IPRs, Supreme Court
